Thirty-Day Results of ABSORB IV Demonstrate that Improvements in Bioresorbable Stent Technology and Technique are Still Needed

DENVER – October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

Current Status of the Left Ventricular Assist Device as a Destination Therapy

Advanced heart failure (AHF) affects approximately 5–10 % of the current 6.6 million people living with heart failure, having a higher incidence in those above 65 years of age.1 The presence of the disease is associated with 50–80 % mortality at 1 year, indicating the need for innovative therapies to manage the burden of this disease.

The Entirely Subcutaneous Defibrillator – A New Generation and Future Expectations

Numerous large clinical trials have demonstrated the benefit of implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death (SCD) in selected populations.1,2 These results and advances in defibrillation therapies have led to an impressive expansion of ICD implants and indications in recent decades.

Left Ventricular Assist Devices in the Management of Heart Failure

Heart failure (HF) is a leading cause of morbidity and mortality worldwide, affecting 1–2 % of the adult population in western countries with incidence of 5–10 per 1000 persons per year.1,2 It is estimated that the prevalence of HF will continue to increase as the population ages and, according to the American Heart Association (AHA), by the year 2030 the prevalence of HF in the US alone will rise to over 8 million patients, representing a 25 % increase compared to the

Cardiac Resynchronisation Therapy and Heart Failure: Perspective from 5P Medicine

The prevalence of heart failure (HF) is still high1 and is rising in developing countries.2 Despite optimal medical therapy, refractory HF is a common occurrence and remains a “global disease requiring global response.”3 The emergence of cardiac resynchronisation therapy (CRT), has brought a new paradigm in the management of HF.